Independent Gateway to Understanding Type 2 Inflammation
Patients with atopic dermatitis (AD) suffer from chronic inflammation of the skin. It is a common and unpredictable skin disease, making it important to find an effective and safe treatment. Abrocitinib is a promising molecule for the potential treatment of AD. If approved, it could prevent inconvenient flares in patients. AD is associated with uncertainty in daily life. The unpredictability…
Crisaborole is indicated for the topical treatment of mild-to-moderate atopic dermatitis. It is effective and safe in treating patients aged ≥2 years with allergic dermatitis irrespective of atopic comorbidities. Crisaborole ointment 2% is an anti-inflammatory inhibitor of phosphodiesterase 4. It is available in the USA for topical treatment targeting paediatric patients with mild-to-moderate allergic dermatitis (AD) who are at an…
The multicentre, randomised JADE-COMPARE trial (NCT03720470), published on March 25, 2021 in the New England Journal of Medicine, showed that the higher dose of experimental oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, showed greater itch reduction after 2 weeks of treatment than dupilumab in patients with moderate to severe atopic dermatitis (AD) [1]. Neither abrocitinib dose differed significantly from dupilumab with respect to most…
The Phase 3 JADE REGIMEN study (NCT03627767) was a 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200mg. The JADE REGIMEN results build on the positive results from the JADE MONO-1 and 2…
The interaction between the nervous system and immune cells has been reported in fungal-infected skin inflammation and psoriasis, but not in atopic dermatitis (AD) [1-3]. Antihistamines are not always effective in treating pruritus in chronic skin inflammation [4]. A recent study by Serhan et al. unraveled how house dust mite allergens can trigger peripheral nociceptive sensory neurons and how these…
The JADE Mono-2 study in adolescent and adult patients with atopic dermatitis (AD) investigated the efficacy and safety of abrocitinib. The results demonstrated significant advantages in clinical signs and symptoms over placebo [1,2]. The randomised, controlled, double-blind, phase 3 trial included 391 patients aged ≥12 years with moderate-to-severe AD from 115 centres worldwide and was presented by Dr Melinda Gooderham…
New data from a pooled analysis of phase 3 trials demonstrated substantial efficacy of JAK-inhibition with baricitinib for head and neck lesions in atopic dermatitis (AD) [1]. The oral JAK1/JAK2 inhibitor baricitinib has already proven its efficacy versus placebo in treating moderate-to-severe AD in the identical, double-blind, randomised, controlled, phase 3 BREEZE-AD1 and BREEZE-AD2 trials. Patients with AD often experience…
The IL-4/IL-13 blocker dupilumab leads to rapid symptom control and itch reduction in children with severe atopic dermatitis (AD), as was demonstrated in the phase 3 LIBERTY AD PEDS study [1]. Previous trials have already shown that dupilumab is effective in adults and adolescents ≥12 years with moderate-to-severe AD inadequately controlled with topical prescription therapies. However, there is also an…
IL-13 plays a key role in pathogenesis of atopic dermatitis (AD). The phase 3 ECZTRA trials demonstrated the remarkable efficacy of the IL-13 blocker tralokinumab in adult patients with moderate-to-severe AD [1]. AD is a chronic inflammatory skin disease. Tralokinumab is a fully human monoclonal antibody designed specifically to neutralise IL-13, a key driver of the underlying inflammation in AD,…
IL-1⍺ blockade is a novel interesting target in atopic dermatitis (AD). In a proof-of-concept study, an IL-1 blocker improved AD in all disease measures [1]. “The rationale behind targeting IL-1⍺ is that Th1 immunity plays a signifying role in adults with chronic AD,” said Prof. Alice Gottlieb (Icahn School of Medicine at Mount Sinai, USA). Under the influence of a…